Compare CTW & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTW | NKTX |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.6M | 198.2M |
| IPO Year | N/A | 2020 |
| Metric | CTW | NKTX |
|---|---|---|
| Price | $2.58 | $2.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.33 |
| AVG Volume (30 Days) | 13.2K | ★ 486.9K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $1.63 |
| 52 Week High | $3.14 | $3.65 |
| Indicator | CTW | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.73 | 52.26 |
| Support Level | $1.92 | $2.59 |
| Resistance Level | $2.56 | $3.34 |
| Average True Range (ATR) | 0.28 | 0.22 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 34.83 | 60.00 |
CTW Cayman operates the web-based HTML5 gaming platform G123.jp, offering free-to-play games based on Japanese animations, including Queen's Blade, So I'm a Spider, So What?, and Goblin Slayer. The platform features 29 games, with 11 in pre-registration. The Group provides a platform for game developers to generate revenue and reach an international audience through shared revenue from players' in-game purchases. It operates in Japan, Singapore, Taiwan, and China, excluding Taiwan, with the majority of revenue derived from Japan, and has one reporting segment focused on game distribution and related services.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.